Australia Health

Argenica Therapeutics (ASX:AGN) reports positive preclinical data as lead drug ARG-007 reduces concussion damage.

Immuron (ASX:IMC) reported global sales of $7.7 million for FY26, marking a 6% increase over the prior comparative period.

Cyclopharm (ASX:CYC) executed an agreement with University Hospitals to install its Technegas system across 11 clinical locations.

Immutep (ASX:IMM) has secured United States patent number 12,673,088 for its cancer immunotherapy combination treatments.

Mesoblast (ASX:MSB) has treated 300 patients in a key clinical trial to validate a new low back pain therapy.

Pacific Edge (ASX:PEB) announced that its Asia Pacific business is advancing towards profitability on a direct-cost basis.

Ryman Healthcare (ASX:RYM) reported 325 sales of retirement living occupation right agreements for the quarter ended June 30.

OncoSil Medical (ASX:OSL) completed three manufacturing validation cycles to establish a local production capability for over 50 device doses.

Regis Healthcare (ASX:REG) announced that CFO Rick Rostolis will retire from his position effective Aug. 31.

Clinuvel (ASX:CUV) secured regulatory approval from Health Canada to market its 16mg SCENESSE drug for adult patients with erythropoietic protoporphyria.

Mesoblast (ASX:MSB) reported a full-year net revenue of US$115 million following increased sales of its approved cellular medicine.

Sigma Healthcare (ASX:SIG) announced that co-founders Sam and Jack Gance may sell up to 20% of their combined $7.7 billion stake.